ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Seattle, WA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near Seattle, WA, USA:

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple ne ...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Atezolizumab
Drug: Placebo

Phase 3

National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP)

Auburn, Washington, United States and 216 other locations

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Renton, Washington, United States and 166 other locations

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Placebo
Drug: Niraparib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Everett, Washington, United States and 199 other locations

This is a Phase II trial to assess feasibility of pembrolizumab + INBRX-106 as a chemotherapy-sparing neoadjuvant therapy. One therapeutic arm is bei...

Enrolling
Triple Negative Breast Cancer
Drug: Pembrolizumab
Drug: INBRX-106

Phase 2

Providence Health & Services
Providence Health & Services

Seattle, Washington, United States and 3 other locations

This is a Phase 2, Multi-Cohort, Open-Label, Multi-Center Study. Cohort 1 will be a single-arm study of intratumoral tavokinogene telseplasmid (TAVO)...

Active, not recruiting
Triple Negative Breast Cancer
Device: Immunopulse
Drug: nab paclitaxel

Phase 2

OncoSec Medical

Seattle, Washington, United States and 13 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Seattle, Washington, United States and 516 other locations

for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...

Active, not recruiting
Breast Cancer
Drug: Tobemstomig
Drug: Nab-Paclitaxel

Phase 2

Roche
Roche

Seattle, Washington, United States and 108 other locations

CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small...

Active, not recruiting
Relapsed Cancer
TNBC - Triple-Negative Breast Cancer
Biological: LYL797

Phase 1

Lyell Immunopharma

Seattle, Washington, United States of America and 17 other locations

vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Drug: Cyclophosphamide

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Seattle, Washington, United States and 192 other locations

The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-...

Enrolling
Triple Negative Breast Cancer
Biological: adagloxad simolenin combined with OBI-821
Other: Standard of care treatment

Phase 3

OBI Pharma

Tacoma, Washington, United States and 140 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems